Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)
What is the purpose of this trial?
The objective in this study is to determine if MRI-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (AS).
Our hypothesis is that MRI alone is adequate to detect progression of prostate cancer in men on active surveillance (AS) after a MRI-US fusion prostate biopsy.
- Ages30 years - 80 years
- Trial withYale University School of Medicine
- Start Date06/10/2015
- End Date01/22/2020
- Last Updated02/22/2018
- Study HIC#1501015246